A Phase 3 interventional study of RAD001 and MMF in Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant, sponsored by Novartis Pharmaceuticals. Completed at 31 sites in 13 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2019-05-31.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Death with a site in Germany — 2 open to participants now, 6 under way, 2 of them phase 3. Death · Germany.
Among the 22 studies in Death with a site in Germany, this one is one of 3 that started in 2012, is one of 4 in phase 3, and was the 6th registered.
456 studies on the registry are indexed under Death; 86 are open to participants now.
Browse Death studies →2 of the 22 studies in Death with a site in Germany are open now. Recruiting first, the newest first:
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 18+
King's College Hospital NHS Trust · Sites in Germany, United Kingdom
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 59 Death studies recruiting now, 44 (75%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is below the median of 163 across 210 interventional studies indexed under Death.
Median enrollment 543 across the 9 interventional studies, 224 across the 13 observational. Of the 15 that completed or were terminated, 3 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 1 study filed under Death — fewer than ten, so there is no comparison to draw.
4 of the studies in Death with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT07312760Universitätsklinikum Hamburg-EppendorfExistential Distress in Advanced Cancer: Comparing a Short-term Psychodynamic Psychotherapy (ORPHYS) to Treatment as Usual (TAU) | 2026-12 |
| NCT07491679University Hospital MuensterIMPULS-NRW: Telemedicine in Specialized Outpatient Palliative Care | 2027-05 |
| NCT07416669King's College Hospital NHS TrustDeath, Dying, Violence and Aggression as Shown on Medical Television Series. | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies in Death with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid regimen after paediatric kidney transplantation. An additional purpose of the study is to assess the effect of the combination of EVR and reduced exposure CNI (TAC) on renal function.
This study is part of the requirements of the Paediatric Investigational Plan approved by Paediatric Committee at the European Medicines Agency (PDCO/EMA) on September 10, 2010, and is intended to support the indication of everolimus in the prevention of acute rejection in paediatric recipients of a renal transplant.
Inclusion Criteria:
Inclusion criteria at baseline:
Inclusion criteria at randomization:
Exclusion Criteria:
Exclusion criteria at baseline:
Exclusion criteria at randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Conversion from MMF to everolimus plus reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
Drug: RAD001
MMF continuation (in combination with tacrolimus and standard dose steroids)
Drug: MMF
Number of Participants Having Reached the Composite Efficacy Endpoint of Biopsy-proven Acute Rejection
To estimate the rate of the composite efficacy endpoint of biopsy-proven acute rejection (BPAR), graft loss or death at 12 months post transplantation in primary paediatric kidney transplant recipients converted at 4-6 weeks post-transplantation from MMF + standard TAC regimen and steroids, to everolimus + reduced dose TAC regimen and steroid withdrawal at 6 months, versus continuation of MMF + standard TAC regimen and steroids.
Time frame: 12 months, 36 months
To Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Abbreviated), at Month 12 and 36
To evaluate renal function assessed by Glomerular Filtration Rate (eGFR) estimated by the Schwartz Formula (abbreviated) (Schwartz, 2009).
Time frame: 12 months and 36 months post-transplantation
Composite Efficacy Endpoint
To evaluate the proportion of patients with the following efficacy events: Biopsy Proven Acute Rejection (BPAR), graft loss or death. The efficacy events will be descriptively summarized by treatment group.
Time frame: at 12 and 36 months post-transplantation
To Evaluate the Severity of BPAR (Acute T-cell Mediated Rejection Only) (Banff 2009)
T-cell mediated rejection severity : Type IA - Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Type IB - Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Type IIA - Mild to moderate intimal arteritis Type IIB - Severe intimal arteritis comprising \> 25% of the lumenal area Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)
Time frame: month 12, month 36
To Evaluate the Time to Event of BPAR
Time to incidence of Event, given in terms of number of participants with an Event according to time interval up to 36 months
Time frame: 36 months
Incidence of Biopsy Proven Antibody Mediated Rejection.
To evaluate the proportion of patients with the following efficacy events: biopsy proven antibody mediated rejection/Steroid resistant BPAR and BPAR treated with T cell depleting therapy.
Time frame: at 12 and 36 months post-transplantation
Chronic Allograft Nephropathy / Interstitial Fibrosis and Tubular Atrophy
To evaluate the proportion of patients with chronic allograft nephropathy (interstitial fibrosis and tubular atrophy, IF/TA) by histopathology and its progression.The term chronic allograft nephropathy was used inappropriately in the protocol and therefore, replaced by interstitial fibrosis and tubular atrophy
Time frame: at 12 and 36 months post-transplantation.
Proteinuria (Urinary Protein/Creatinine Ratio)
The urinary protein/creatinine ratio will be descriptively summarized by treatment group at each visit. The incidence rate of patients with proteinuria will be categorized in \<0.2 g/mg/mg, 0.2\<2.0 mg/mg and ≥ 2.0 mg/mg and summarized by treatment groups at each visit.
Time frame: at 12 and 36 months post-transplantation
Growth/Development : Weight, Height, BMI : Change From Baseline
Evaluation of the potential effects upon the bone growth. The Z-score is a statistical tool which helps to assess data (here child growth parameters) relative to a reference or standard population. The Z-score describes the distance and direction of an observation away from the population median (or mean, however, here the median was used). A negative Z-score shows that data are lower than the median of the standard population, a positive Z-score shows that data are higher than the median of the standard population, and a Z-score of zero shows that the data are equal to the median of the standard population. The more the Z-score is distant from 0, the more expressed is for example underweight or overweight.
Time frame: month 12 , month 36 post transplantation.
Evaluation of Evolution of Renal Allograft Function Over Time
results given as eGFR values by time interval
Time frame: baseline, 6 months, 12 months , 24 months, 36 months
To Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Extended), at Month 12
To evaluate renal function assessed by Glomerular Filtration Rate (eGFR) estimated by the Schwartz Formula (extended) (Schwartz, 2009). Results given as change from randomization
Time frame: 12 months post-transplantation
Full Analysis set (FAS) 106 enrolled and randomized patients except misrandomized Per Protocol set (PPS) 90 patients in the FAS without major protocol deviations Safety set (SAF) 106 randomized patients who received at least one dose of study drug
| Milestone | EVR+rTAC | MMF+sTAC |
|---|---|---|
| Started | 52 | 54 |
| Completed | 47 | 51 |
| Not completed | 5 | 3 |
| Withdrew: Withdrawal by subject | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Administrative problems | 2 | 0 |
To estimate the rate of the composite efficacy endpoint of biopsy-proven acute rejection (BPAR), graft loss or death at 12 months post transplantation in primary paediatric kidney transplant recipients converted at 4-6 weeks post-transplantation from MMF + standard TAC regimen and steroids, to everolimus + reduced dose TAC regimen and steroid withdrawal at 6 months, versus continuation of MMF + standard TAC regimen and steroids.
| Participants | EVR+rTAC | MMF+sTAC |
|---|---|---|
| 12 months | 5 | 3 |
| 36 months | 5 | 5 |
To evaluate renal function assessed by Glomerular Filtration Rate (eGFR) estimated by the Schwartz Formula (abbreviated) (Schwartz, 2009).
| mL/min/1.73m2 | EVR+rTAC | MMF+sTAC |
|---|---|---|
| 12 months | 76.7 ± 3.66 | 71.7 ± 3.56 |
| 36 months | 68.1 ± 3.45 | 67.3 ± 3.54 |
To evaluate the proportion of patients with the following efficacy events: Biopsy Proven Acute Rejection (BPAR), graft loss or death. The efficacy events will be descriptively summarized by treatment group.
| Participants | EVR+rTAC | MMF+sTAC |
|---|---|---|
| month 12 composite efficacy endpoint | 5 | 3 |
| graft loss 12 months | 0 | 0 |
| death 12 months | 0 | 0 |
| acute rejection 12 months | 5 | 4 |
| treated acute rejection 12 months | 5 | 4 |
| Biopsy proven acute rejection 12 months | 5 | 3 |
| treated Biopsy proven acute rejection 12 months | 5 | 3 |
| month 36 composite efficacy endpoint | 5 | 5 |
| graft loss 36 months | 1 | 2 |
| death 36 months | 0 | 0 |
| acute rejection 36 months | 5 | 7 |
| Biopsy proven acute rejection 36 months | 5 | 5 |
| treated Biopsy proven acute rejection 36 months | 5 | 5 |
T-cell mediated rejection severity : Type IA - Significant interstitial infiltration (\> 25% of parenchyma) and foci of moderate tubulitis (\> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Type IB - Significant interstitial infiltration (\> 25% of parenchyma) and foci of severe tubulitis (\> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Type IIA - Mild to moderate intimal arteritis Type IIB - Severe intimal arteritis comprising \> 25% of the lumenal area Type III - Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)
| Participants | EVR+rTAC | MMF+sTAC |
|---|---|---|
| month 12 grade IA | 3 | 1 |
| month 12 grade IB | 1 | 0 |
| month 12 grade IIA | 0 | 2 |
| month 12 grade IIB | 0 | 0 |
| month 12 grade III | 0 | 0 |
| month 36 grade IA | 3 | 1 |
| month 36 grade IB | 2 | 0 |
| month 36 grade IIA | 0 | 1 |
| month 36 grade IIB | 0 | 1 |
| month 36 grade III | 0 | 1 |
Time to incidence of Event, given in terms of number of participants with an Event according to time interval up to 36 months
| Participants | EVR+rTAC | MMF+sTAC |
|---|---|---|
| day 1-7 | 0 | 0 |
| day 8-14 | 0 | 0 |
| day 15-28 | 1 | 0 |
| day 29-56 | 0 | 0 |
| day 57-84 | 0 | 0 |
| day 85-150 | 2 | 2 |
| day 151- 240 | 0 | 0 |
| day 241-330 | 1 | 2 |
| day 331- 510 | 0 | 1 |
| day 511-690 | 1 | 0 |
| day 691-870 | 0 | 0 |
| day 871-1050 | 0 | 0 |
| after day 1050 | 0 | 0 |
To evaluate the proportion of patients with the following efficacy events: biopsy proven antibody mediated rejection/Steroid resistant BPAR and BPAR treated with T cell depleting therapy.
| Participants | EVR+rTAC | MMF+sTAC |
|---|---|---|
| patients with BPAR at 12 months | 7 | 8 |
| BPAR Steroid resistant,12 months | 1 | 0 |
| BPAR, T Cell depleting therapy 12 months | 1 | 1 |
| patients with BPAR at 36 months | 6 | 12 |
| BPAR Steroid resistant,36 months | 1 | 2 |
| BPAR, T Cell depleting therapy 36 months | 2 | 1 |
To evaluate the proportion of patients with chronic allograft nephropathy (interstitial fibrosis and tubular atrophy, IF/TA) by histopathology and its progression.The term chronic allograft nephropathy was used inappropriately in the protocol and therefore, replaced by interstitial fibrosis and tubular atrophy
| Participants | EVR+rTAC | MMF+sTAC |
|---|---|---|
| 12 months | 3 | 3 |
| 36 months | 11 | 7 |
The urinary protein/creatinine ratio will be descriptively summarized by treatment group at each visit. The incidence rate of patients with proteinuria will be categorized in \<0.2 g/mg/mg, 0.2\<2.0 mg/mg and ≥ 2.0 mg/mg and summarized by treatment groups at each visit.
| Participants | EVR+rTAC | MMF+sTAC |
|---|---|---|
| Baseline < 200mg/g | 1 | 2 |
| Baseline 200 - < 2000 mg/g | 12 | 12 |
| Baseline >= 2000 mg/g | 14 | 15 |
| Month 12 < 200mg/g | 19 | 28 |
| Month 12 200 - < 2000 mg/g | 13 | 11 |
| Month 12 >= 2000 mg/g | 0 | 0 |
| Month 36 < 200mg/g | 23 | 23 |
| Month 36 200 - < 2000 mg/g | 10 | 11 |
| Month 36 >= 2000 mg/g | 1 | 0 |
Evaluation of the potential effects upon the bone growth. The Z-score is a statistical tool which helps to assess data (here child growth parameters) relative to a reference or standard population. The Z-score describes the distance and direction of an observation away from the population median (or mean, however, here the median was used). A negative Z-score shows that data are lower than the median of the standard population, a positive Z-score shows that data are higher than the median of the standard population, and a Z-score of zero shows that the data are equal to the median of the standard population. The more the Z-score is distant from 0, the more expressed is for example underweight or overweight.
| z score | EVR+rTAC | MMF+sTAC |
|---|---|---|
| Height month 12 | 0.37 ± 0.625 | 0.20 ± 0.537 |
| Height month 36 | 0.72 ± 1.131 | 0.39 ± 0.776 |
| Weight month 12 | 0.30 ± 0.732 | 0.42 ± 0.747 |
| Weight month 36 | 0.61 ± 0.987 | 0.82 ± 1.268 |
| BMI month 12 | 0.00 ± 0.716 | 0.24 ± 0.980 |
| BMI month 36 | 0.02 ± 0.860 | 0.47 ± 1.231 |
results given as eGFR values by time interval
| ml/min/1.73m2 | EVR+rTAC | MMF+sTAC |
|---|---|---|
| baseline | 14.2 ± 11.38 | 13.1 ± 15.62 |
| month 6 | 76.6 ± 28.29 | 68.3 ± 21.02 |
| month 12 | 76.9 ± 21.61 | 67.8 ± 23.57 |
| month 24 | 72.9 ± 28.43 | 68.6 ± 23.26 |
| month 36 | 68.2 ± 21.60 | 69.6 ± 20.01 |
To evaluate renal function assessed by Glomerular Filtration Rate (eGFR) estimated by the Schwartz Formula (extended) (Schwartz, 2009). Results given as change from randomization
| mL/min/1.73m2 | EVR+rTAC | MMF+sTAC |
|---|---|---|
| To Evaluate Renal Function, Assessed by Glomerular Filtration Rate (eGFR) and Estimated by the Schwartz Formula (Extended), at Month 12 | 4.6 ± 11.94 | -0.0 ± 23.92 |
Collected over up to 36 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EVR+rTAC | 0/52 (0%) | 0/52 (0%) | 46/52 (88.5%) |
| MMF+sTAC | 0/54 (0%) | 0/54 (0%) | 48/54 (88.9%) |
| Event | EVR+rTAC | MMF+sTAC |
|---|---|---|
| NasopharyngitisInfections and infestations | 16/52 | 6/54 |
| DiarrhoeaGastrointestinal disorders | 13/52 | 16/54 |
| Urinary tract infectionInfections and infestations | 13/52 | 15/54 |
| PyrexiaGeneral disorders | 14/52 | 11/54 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/52 | 10/54 |
| AnaemiaBlood and lymphatic system disorders | 10/52 | 11/54 |
| HeadacheNervous system disorders | 10/52 | 11/54 |
| VomitingGastrointestinal disorders | 10/52 | 8/54 |
| NeutropeniaBlood and lymphatic system disorders | 2/52 | 10/54 |
| Aphthous ulcerGastrointestinal disorders | 9/52 | 1/54 |
| Age, Customized(Participants) | EVR+rTAC | MMF+sTAC | Total |
|---|---|---|---|
| 1 to <11 years | 26 | 27 | 53 |
| 11 <= 18 years | 26 | 27 | 53 |
| Sex/Gender, Customized(Participants) | EVR+rTAC | MMF+sTAC | Total |
|---|---|---|---|
| Male | 29 | 31 | 60 |
| Female | 23 | 23 | 46 |
| Race/Ethnicity, Customized(Participants) | EVR+rTAC | MMF+sTAC | Total |
|---|---|---|---|
| Caucasian | 42 | 47 | 89 |
| Black | 1 | 0 | 1 |
| Asian | 3 | 2 | 5 |
| Other | 6 | 5 | 11 |
Plan to share: Undecided — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Aug 2012 to primary completion in Oct 2016, 49 months.
Results were first posted in May 2019, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus